SAN FRANCISCO – The J.P. Morgan Healthcare Conference might be reluctant to change, dedicated to the same (crowded) hotel venue for the past 34 years, but it is open to a rapidly growing group of attendees, inviting a substantial number of people from China.
SHANGHAI – Canbridge Life Sciences Inc. has confirmed the existence of ligand CD95 in Chinese glioblastoma patients after completing the first such biomarker study of its kind on the mainland. The study demonstrated a high degree of CD95 ligand expression consistency between geographically diverse Chinese and Western glioblastoma multiforme patients.
SAN FRANCISCO – While many of China's biopharmaceutical company executives flew across the Pacific for the J.P. Morgan Healthcare Conference, they kicked off the week with the Bayhelix 13th Annual Conference, a confab of China's best and brightest. The group's founding members were ambitious China-born scientists and managers working in the U.S. looking for camaraderie. Today, they are leaders in the field, heading up their own well-financed biopharma, med tech, service and investment companies.
SHANGHAI – Zai Labs Ltd., of Shanghai, has done it again, this time raising more than $100 million from seasoned health care venture firms led by Advantech Capital and Orbimed. The trio of Zai's series A backers – Qiming Ventures, Sequoia and TF Capital – also continued their support in this second round.
SAN FRANCISCO – While many of China's biopharmaceutical company executives flew across the Pacific for the J.P. Morgan Healthcare Conference, they kicked off the week with the Bayhelix 13th Annual Conference, a confab of China's best and brightest.
SHANGHAI – Zai Labs Ltd., of Shanghai, has done it again, this time raising more than $100 million from seasoned health care venture firms led by Advantech Capital and Orbimed. The trio of Zai's series A backers – Qiming Ventures, Sequoia and TF Capital – also continued their support in this second round.
SHANGHAI – Canbridge Life Sciences Inc. has confirmed the existence of ligand CD95 in Chinese glioblastoma patients after completing the first such biomarker study of its kind on the mainland. The study demonstrated a high degree of CD95 ligand expression consistency between geographically diverse Chinese and Western glioblastoma multiforme patients.
SHANGHAI – Wuxi Healthcare Ventures closed a fundraising round at $290 million – attracting almost 50 percent more capital than was initially sought – and will now get back to the business of continuing the investment strategy developed with its first fund: find in the U.S, build in China.
SHANGHAI – Wuxi Healthcare Ventures closed a fundraising round at $290 million – attracting almost 50 percent more capital than was initially sought – and will now get back to the business of continuing the investment strategy developed with its first fund: find in the U.S,, build in China.
